GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mankind Pharma Ltd (BOM:543904) » Definitions » Earnings per Share (Diluted)

Mankind Pharma (BOM:543904) Earnings per Share (Diluted) : ₹47.69 (TTM As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Mankind Pharma Earnings per Share (Diluted)?

Mankind Pharma's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was ₹11.74. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was ₹47.69.

Mankind Pharma's EPS (Basic) for the three months ended in Mar. 2024 was ₹11.76. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was ₹47.75.

Mankind Pharma's EPS without NRI for the three months ended in Mar. 2024 was ₹11.74. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was ₹47.69.

During the past 12 months, Mankind Pharma's average EPS without NRIGrowth Rate was 49.00% per year. During the past 3 years, the average EPS without NRIGrowth Rate was 15.80% per year.

During the past 5 years, Mankind Pharma's highest 3-Year average EPS without NRI Growth Rate was 15.80% per year. The lowest was 6.20% per year. And the median was 11.00% per year.


Mankind Pharma Earnings per Share (Diluted) Historical Data

The historical data trend for Mankind Pharma's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mankind Pharma Earnings per Share (Diluted) Chart

Mankind Pharma Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24
Earnings per Share (Diluted)
25.72 31.59 35.78 32.00 47.68

Mankind Pharma Quarterly Data
Mar20 Mar21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.13 12.15 12.49 11.31 11.74

Competitive Comparison of Mankind Pharma's Earnings per Share (Diluted)

For the Drug Manufacturers - Specialty & Generic subindustry, Mankind Pharma's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mankind Pharma's PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mankind Pharma's PE Ratio distribution charts can be found below:

* The bar in red indicates where Mankind Pharma's PE Ratio falls into.



Mankind Pharma Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Mankind Pharma's Earnings Per Share (Diluted) for the fiscal year that ended in Mar. 2024 is calculated as

Diluted Earnings Per Share (A: Mar. 2024 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(19128.967-0)/401.195
=47.68

Mankind Pharma's Earnings Per Share (Diluted) for the quarter that ended in Mar. 2024 is calculated as

Diluted Earnings Per Share (Q: Mar. 2024 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(4712.385-0)/401.392
=11.74

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹47.69

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


Mankind Pharma  (BOM:543904) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Mankind Pharma Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Mankind Pharma's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Mankind Pharma (BOM:543904) Business Description

Traded in Other Exchanges
Address
262, Okhla Industrial Estate, Phase-III, New Delhi, IND, 110020
Mankind Pharma Ltd is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. It operates at the intersection of Indian pharmaceutical formulations and consumer healthcare sectors with the aim of providing quality products at affordable prices and has an established track record of building and scaling brands in-house. The company's brands include Manforce, Prega News and Gas-O-Fast.

Mankind Pharma (BOM:543904) Headlines

No Headlines